Introduction
============

Patients with hip fracture are commonly encountered in orthopedic and geriatric wards.[@b1-cia-10-1259] These patients often suffer from several comorbidities[@b2-cia-10-1259] and therefore require considerable nursing and medical care, in addition to the specific care needed for the hip fracture. Presence of comorbidities increases the risk of complications and frequently causes increased suffering with prolonged hospital stay[@b3-cia-10-1259]--[@b5-cia-10-1259] and increased mortality rate.[@b6-cia-10-1259] Few studies have been conducted with large samples to examine sex differences with focus on the effects of specific risk factors for short-term serious complications. It has been found that men more often suffer comorbidities at the time of hip fracture, that they are twice as likely to die after a hip fracture compared to women, and that the cause of death is dominated by infectious diseases such as pneumonia, influenza, and septicemia.[@b7-cia-10-1259] Another study has confirmed that men are more likely to die from respiratory disease, malignant neoplasm, and circulatory disease compared to women.[@b8-cia-10-1259] However, Endo et al[@b9-cia-10-1259] found that there was no difference across sex when considering the number of comorbidities prior to surgery, but men had a worse physical status when assessed according to the American Society of Anaesthesiologists (ASA) score. In the same study, men had a higher proportion of one or more postoperative complications, with particular focus on pneumonia, arrhythmia, delirium, and pulmonary embolism.[@b9-cia-10-1259]

In 2009, we published a study analyzing sex differences in patients with a hip fracture and found that cognitive function in men was strongly associated with a higher risk of loss of walking ability and mortality.[@b10-cia-10-1259] In another report from the same population, we analyzed associated factors for mortality in men and women with a hip fracture and presented a prognostic model including age, sex, ASA, and cognitive function.[@b11-cia-10-1259]

Considering the serious complications that could occur after hip fracture surgery, especially in men, it would be of great value to better understand factors related to postoperative complications at admission in order to offer optimal care for patients at high risk.

The aim of the present study was to analyze sex differences and other possible factors associated with short-term complications. In contrast to our previous reports from this cohort, this report focuses on perioperative complications and possible associated factors within 4 months after surgery.

Materials and methods
=====================

All patients admitted with a hip fracture to any of the four university hospitals in Stockholm were consecutively included in a prospective cohort study throughout 2003.[@b10-cia-10-1259] The patients were enrolled for 1 year and then followed for 2 years. Patients with pathologic hip fractures, such as metastatic fractures, malign and benign bone cyst, and fracture due to Paget's disease, and patients younger than 65 years were excluded. The overall aim of the initial study was to describe the population with hip fracture in a geographically defined urban area and to evaluate the effect of cognitive function and sex on functional outcome.[@b10-cia-10-1259] This study aims to further evaluate the sex effect on complications within 4 months after surgery. Patients were treated according to the Swedish National Guidelines.[@b12-cia-10-1259] The guidelines recommend surgery within 24 hours, and encouraged early mobilization, and restricted time for the routine use of perioperative urinary catheter. Data collection was performed by a trained research nurse at each hospital and was then confirmed by the senior orthopedic consultant responsible for the study. At inclusion, the research nurse made a review of the medical records and carried out a structured interview with each patient according to the study protocol based on the national register RIKSHÖFT--standardized audit of hip fractures in Europe (SAHFE).[@b13-cia-10-1259] Data collection was performed at baseline and at 4 months. Proxy respondents were interviewed if the patients were unable to provide reliable answers.

Each patient's physical and mental status on admission to the hospital were regarded as baseline. The index episode was defined as the patient status during the time period from admission to discharge from the hospital. Patient interviews were carried out during the index episode and at follow-up after 4 months.

The patient's current residence status was defined as living in own home or in an institution, which would include nursing homes or other staffed facilities, for example. Activities of daily living (ADL) status was recorded according to the Katz ADL Index.[@b14-cia-10-1259] The Katz ADL index status is based on an evaluation of the functional dependence or independence of patients in bathing, dressing, going to the toilet, transferring, continence, and feeding. ADL index A indicates independence in all six functions, index B independence in all but one of the six functions. Indexes C--G indicate dependence in bathing and at least one more function. Presence or absence of concomitant diseases (comorbidity) was based on the medical history obtained from the patient, a proxy, and the medical records. Comorbidities were classified as cardiovascular disease, stroke, pulmonary disease, renal disease, diabetes mellitus, rheumatoid arthritis, Parkinson disease, and malignancy. The patient's smoking status was recorded as "current smoker" or "nonsmoker". Experienced orthopedic surgeons classified the hip fractures according to the SAHFE protocol.[@b13-cia-10-1259] The attending anesthesiologist assessed the patient's health status using the ASA score.[@b15-cia-10-1259] Cognitive status was assessed during the index period using the Short Portable Mental Status Questionnaire (SPMSQ), which is a 10-item questionnaire. A range of 0--2 correct answers indicates severe cognitive dysfunction, 3--5 moderate dysfunction, 6--7 mild dysfunction, and 8--10 lucid.[@b16-cia-10-1259] For the purpose of this study, we dichotomized the answers into two categories: cognitive dysfunction (ie, 0--7 correct answers) or no cognitive dysfunction (8--10 correct answers). In cases where the test was not conducted, patients were classified as having cognitive dysfunction if they had a diagnosis or known history of dementia; otherwise they were recorded as missing. Time to surgery was registered in days from admission to the hospital.

Pressure ulcers were classified as grades I--IV according to the European Ulcer Advisory Panel (EPUAP 1999).[@b17-cia-10-1259] The following medical and general complications, as defined in the SAHFE protocol,[@b13-cia-10-1259] were used for the purpose of this study: pneumonia, cardiac complications (cardiac failure, arrhythmia, angina), deep venous thrombosis, pulmonary embolism, wound infection (superficial and deep), urinary tract infection (UTI), acute renal failure, gastrointestinal bleeding, myocardial infarction, cerebrovascular lesion, and pressure ulcer.

Complications were identified by collecting information from medical records. Pressure ulcers were recorded on admission, during initial hospital stay, and at the time of discharge. Information on mortality was obtained from each hospital's discharge register or from a proxy.

Statistical methods
-------------------

Data were presented as mean ± SD (standard deviation) or as indicated. Categorical and nominal data were summarized as percentages (within sex group) and tested for sex differences with the *χ*^2^ test. The crude association between baseline variables and the most frequent complications is described and presented as odds ratios (ORs), with 95% confidence interval (CI), and *P*-values. Associated variables were entered into logistic regression models using the stepwise selection procedure, one model for each selected complication. All variables in the regression models were tested for interactions. All results are presented as ORs with their respective 95% CIs. All tests were two-sided, with the level of significance set at *P*\<0.05. Analyses were performed with IBM SPSS Statistics 19 (IBM Corporation, Armonk, NY, USA).

The study was conducted according to the Helsinki Declaration, and the local ethics committee approved all protocols.

Results
=======

Of the initial 2,134 patients with a history of hip fracture, 179 patients were younger than 65 years and hence excluded from the study. The study sample consisted of 1,955 elderly patients. Of them, 12 patients died before surgery. Interview data were missing at baseline for an additional 28 patients, leaving just 1,915 patients (1,435 women and 480 men) in the final analysis. Baseline demographics, fracture type, and medical conditions are presented by sex in [Table 1](#t1-cia-10-1259){ref-type="table"}.

Comorbidity -- sex differences at baseline
------------------------------------------

Mean age was higher in the female population, at 84±6.8 vs 82±7.4 years in men (*P*\<0.001). Male sex was associated with a higher percentage ASA 3--4, 69% vs 61% in female (*P*=0.002). Men also had more comorbidities, mean, 1.6 (SD, 1.08) compared to 1.4 (SD, 0.96) in women (*P*\<0.001). Cardiovascular disease was found to be 66% among men and 67% among women (*P*=0.824). Significantly more men had a history of stroke (22% men vs 14% women, *P*\<0.001), pulmonary disease (20% men vs 15% women, *P*=0.002), Parkinson disease (5% men vs 3% women, *P*=0.017), renal disease (6% men vs 4% women, *P*=0.038), and malignancy (21% men vs 14% women, *P*\<0.001). In the male group 14% were suffering from diabetes mellitus vs 11% in the female group (*P*=0.097). Rheumatoid arthritis was found to be 5% among men and 7% among women (*P*=0.169). Fifty-nine percent of males and 58% of females had a cognitive dysfunction, according to the SPMSQ (*P*=0.594) ([Table 1](#t1-cia-10-1259){ref-type="table"}).

Complications -- sex differences
--------------------------------

The overall complication rate was 59% in the male group vs 56% in the female group (*P*=0.119). About 14% of male patients suffered from pneumonia compared to 6% women (*P*\<0.001), and 18% of the men had a cardiac complication compared to 13% of the women (*P*=0.018). Female sex predisposed to UTI, 30% vs 23% in males (*P*=0.001). Mortality was higher in the male group when compared with women, both within 30 days (15% vs 10%, respectively, *P*=0.001) and at 4 month follow-up (24% vs 14%, respectively, *P*=0.001) ([Table 2](#t2-cia-10-1259){ref-type="table"}).

Associations between baseline variables and complications
---------------------------------------------------------

Sex, age, ASA, time-to-surgery, cardiovascular or pulmonary disease, and cognitive function emerged as significantly associated with complications. In the crude analysis, cognitive dysfunction had a negative association with pressure ulcer, cardiac complication, and pneumonia ([Table 3](#t3-cia-10-1259){ref-type="table"}). A history of stroke did not correlate with any of the complications. A similar lack of correlation was found for a history of diabetes mellitus.

Patients with pneumonia had 2.6 times higher odds (OR: 2.6, 95% CI: 1.7--3.9, *P*\<0.001) and patients with cardiac complications 3.9 higher odds (OR: 3.9, 95% CI: 2.9--5.4, *P*\<0.001) of increased 30-day mortality. At 4 months, the mortality was still 2.2 times more likely in patients with pneumonia (OR: 2.2, 95% CI: 1.5--3.2, *P*\<0.001) and 2.5 times more likely in patients with cardiac complication (OR: 2.5, 95% CI: 1.8--3.3, *P*\<0.001) ([Table 3](#t3-cia-10-1259){ref-type="table"}).

The effect of the status at baseline on the four most common complications was analyzed in a stepwise logistic regression analysis ([Table 4](#t4-cia-10-1259){ref-type="table"}). Female sex posed a higher risk for UTI, whereas male sex was associated with a higher risk of pneumonia. Cardiac complications did not associate with sex. Cognitive dysfunction, present pulmonary disease, and male sex were the strongest factors related to the development of pneumonia. Surgical delay was associated with cardiac complications and increased incidence of developing pressure ulcer.

Discussion
==========

In this study, we confirm that before surgery, men with hip fracture already have a poorer health status and higher comorbidity rates than do women, resulting in a twofold increased risk of pneumonia and also an increased risk of cardiac complications.

Cognitive dysfunction increased the risk of any kind of complication and was, together with present pulmonary disease, a dominating factor related to pneumonia in men. Delayed surgery seems to increase the risk for cardiac complications and should be avoided if possible. It is important to consider the sex perspective early on together with cardiopulmonary comorbidity and cognitive dysfunction to be able to counteract serious complications that may lead to death.

The relatively high complication rate compared to other similar studies may be explained by our approach of including all patients admitted for a hip fracture; in other words, that we also included patients with cognitive dysfunction. Cognitive dysfunction is known to be associated with a negative outcome after a hip fracture. The SPMSQ 10-item questionnaire has been reported to provide relevant information about the cognitive status of patients with hip fractures.[@b18-cia-10-1259] We have previously reported the negative impact of severe cognitive dysfunction on mortality.[@b11-cia-10-1259] Patients with mild to moderate cognitive dysfunction also sustain a high risk of developing complications[@b19-cia-10-1259] that are even harder to identify in the clinical setting.[@b18-cia-10-1259] In this study, we found that cognitive dysfunction increased the risk for all complications, such as UTI, pressure ulcer, cardiac complication, and pneumonia. We also found that mental impairment was the strongest predictor for pneumonia in men, besides having already present pulmonary disease. We therefore recommend the use of an instrument like the SPMSQ at the time of admission to identify these patients. We found that present pulmonary disease was associated with pneumonia and was also more common among men. It is known from previous studies that chest infection and cardiovascular disease are the most common postoperative complications after hip fracture and may lead to increased mortality.[@b20-cia-10-1259]--[@b22-cia-10-1259] This is in accordance with our findings, which also show an increased mortality after a diagnosed pneumonia. Chatterton et al[@b20-cia-10-1259] have also shown that male sex together with increasing age and comorbidity were associated with mortality during hospital stay as well as pneumonia and cardiovascular disease. The result from our study highlights further the need to also consider the sex aspect when assessing the patients' risk for serious complications such as pneumonia or cardiac complications. Despite this knowledge, it seems that the care of these patients needs to be improved, for example, by taking into account male sex as a strong risk factor, considering a more active pre- and postoperative physiotherapeutic treatment, and starting antibiotic treatment sooner. Patients with cardiac disease need to be identified early to be able to consider a more active pre- and postoperative treatment. Under optimum conditions, there is a clear treatment algorithm that includes cardiac evaluation such as adjustment of fluid balance, hemoglobin, and saturation. Assessment by a cardiologist already at the emergency ward should be considered, also including a plan for follow-up during the hospital stay. In certain orthopedic clinics in Sweden, there is now a staff geriatrician, and this has been a valuable contribution to optimize the medical treatment of hip fracture patients.

Somewhat surprising, a previous history of stroke did not correlate with any complication, but identical results have also been reported previously.[@b23-cia-10-1259] In the current study, UTI was identified if antibiotics were provided for this condition. UTI was found to be the most common complication, which is in line with several other studies.[@b3-cia-10-1259],[@b5-cia-10-1259],[@b24-cia-10-1259] Still, the present incidence was even higher than reported by others.[@b25-cia-10-1259],[@b26-cia-10-1259] This may be explained by the fact that we followed all patients up to 4 months after the fracture. Time to surgery was associated with an increased incidence of pressure ulcers, which is consistent with prior findings.[@b27-cia-10-1259]--[@b29-cia-10-1259] Furthermore, cardiac complications were associated with delayed time to surgery. Previous studies have shown the importance of reduced waiting time to surgery to increase the patients possibility to return to independent living,[@b29-cia-10-1259] to reduce hospital stay, and possibly decrease complication rate and mortality.[@b30-cia-10-1259] The Swedish Board has placed a major focus on this issue and demands an annual account of the number of patients with hip fracture who have had surgery within 24 hours. This time limit is also linked to economic compensation, and this could be one way to raise the awareness of the importance of providing a fast track to surgery for patients with hip fracture.[@b12-cia-10-1259] More than half the number of patients in our study had a cardiovascular disease. This comorbidity could require optimization of the patients' health condition before surgery, which in turn could lead to a delay. The question is how to balance these two demands. In a recent review article, it was suggested that we need a more active approach in the preoperative risk assessment, medical and orthopedic comanagement, and perioperative monitoring to be able to operate on the patient within time limits and as safe as possible.[@b31-cia-10-1259] We agree that the preoperative risk assessment is of importance and that it should be carried out systematically using a validated and manageable instrument. In a study evaluating the impact of surgical timing on surgical outcomes, the orthopedic Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM) was used. The study showed a small improvement of the physiological score from admittance to before surgery and that the POSSUM may be used to identify patients with a higher risk for morbidity if surgery was delayed over 24 hours.[@b32-cia-10-1259]

The strengths of this study are the large number of patients as well as the inclusion of patients with cognitive dysfunction. Cognitive dysfunction is often an exclusion criterion in prospective studies of hip fracture patients. The other strengths of the study are the use of validated instruments and protocols, for example, as in our use of the SAFHE, as well as the thorough review of all the charts. These were performed by specially trained research nurses who also interviewed all the patients. There are several limitations of the study. The study did not include current medications, laboratory parameters, or secondary causes of osteoporosis that could have further contributed to the assessment of the patients' risk of mortality. A possible limitation was the missing data which, however, only comprised 1.4% of the patients and therefore is unlikely to affect the outcome.

Conclusion
==========

Before surgery, men with hip fracture already have a poorer health status and higher comorbidity rate than women, resulting in a twofold increased risk of pneumonia and also an increased risk of cardiac complications. Cognitive dysfunction and present pulmonary disease were related to pneumonia in men. Delayed surgery seems to increase the risk for cardiac complications. It is important to consider the sex perspective early on together with cardiopulmonary comorbidity and cognitive dysfunction to be able to counteract serious complications that may lead to death.
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###### 

Baseline demographics in 1,915 patients aged \>65 years with a hip fracture

                                                                          Women        Men   *P*[\*](#tfn1-cia-10-1259){ref-type="table-fn"}             
  ----------------------------------------------------------------------- ------------ ----- ------------------------------------------------- --------- ---------
  Age, mean (SD)                                                          84 (6.8)           82 (7.4)                                          65--101   \<0.001
  Residence[a](#tfn2-cia-10-1259){ref-type="table-fn"}                                                                                                   
   Own home                                                               1,077        76    373                                               80        0.153
   Institution                                                            334          24    96                                                20        
  Activities of daily living[b](#tfn3-cia-10-1259){ref-type="table-fn"}                                                                                  
   Katz A--B                                                              986          73    312                                               70        0.138
   Katz C--G                                                              357          27    135                                               30        
  Type of fracture[c](#tfn4-cia-10-1259){ref-type="table-fn"}                                                                                            
   Cervical                                                               668          48    255                                               53        0.004
   Pertrochanteric                                                        655          46    181                                               38        
   Subtrochanteric                                                        92           6     44                                                9         
  ASA score[d](#tfn5-cia-10-1259){ref-type="table-fn"}                                                                                                   
   ASA 1--2                                                               557          39    147                                               31        0.002
   ASA 3--4                                                               872          61    328                                               69        
  Number of comorbidities[e](#tfn6-cia-10-1259){ref-type="table-fn"}                                                                                     
   Mean, (SD), median                                                     1.4 (0.96)   1     1.6 (1.08)                                        2         \<0.001
   0--1                                                                   847          60    230                                               48        
   ≥2                                                                     568          40    247                                               52        \<0.001
  Specific comorbidity                                                                                                                                   
   Cardiovascular disease                                                 951          67    317                                               66        0.824
   Stroke                                                                 230          14    94                                                22        \<0.001
   Pulmonary disease                                                      206          15    97                                                20        0.002
   Renal disease                                                          52           4     28                                                6         0.038
   Diabetes                                                               156          11    66                                                14        0.097
   Rheumatoid arthritis                                                   100          7     25                                                5         0.169
   Parkinson's disease                                                    37           3     23                                                5         0.017
   Malignancy                                                             198          14    100                                               21        \<0.001
  Cognitive dysfunction[f](#tfn7-cia-10-1259){ref-type="table-fn"}        775          58    262                                               59        0.594
  Pressure ulcer at admission                                                                                                                            
   Grade I                                                                54           4     14                                                3         0.392
   Grade II--IV                                                           52           4     17                                                4         0.944
  Surgery same day or day after admission                                 1,092        76    357                                               74        0.446

**Notes:**

Chi-square tests (one-way ANOVA for mean age), women vs men.

Missing: 35;

missing: 125;

missing: 20;

missing: 11;

missing: 23;

according to SPMSQ (0--7).

**Abbreviations:** ASA, American Society of Anesthesiologists; SD, standard deviation; SPMSQ, Short Portable Mental Status Questionnaire; ANOVA, analysis of variance.

###### 

Complications 0--4 months after a hip fracture in 1,915 patients aged ≥65 years

                                                                Women   Men   *P[\*](#tfn9-cia-10-1259){ref-type="table-fn"}*        
  ------------------------------------------------------------- ------- ----- ------------------------------------------------- ---- ---------
  Number of complications                                                                                                            
   None                                                         613     44    194                                               42   0.119
   One                                                          500     35    156                                               33   
   Two or more                                                  290     21    118                                               25   
  Type of complication                                                                                                               
   Pressure ulcer[a](#tfn10-cia-10-1259){ref-type="table-fn"}   248     18    96                                                20   0.200
   Urinary tract infection                                      435     30    109                                               23   0.001
   Cardiac complication                                         191     13    85                                                18   0.018
   Pneumonia                                                    79      6     65                                                14   \<0.001
   Wound infection, superficial                                 69      5     16                                                3    0.174
   Wound infection, deep                                        24      2     9                                                 2    0.768
   Acute renal failure                                          32      2     10                                                2    0.416
   Gastrointestinal bleeding                                    27      2     9                                                 2    0.993
   Myocardial infarction                                        49      3     18                                                4    0.729
   Cerebrovascular lesion                                       27      2     11                                                2    0.577
   Pulmonary embolism                                           14      1     5                                                 1    0.899
   Deep venous thrombosis                                       17      1     4                                                 1    0.899
  Mortality                                                                                                                          
   Mortality, 30 days                                           136     10    74                                                15   \<0.001
   Mortality, 0--4 months                                       207     14    116                                               24   \<0.001

**Notes:**

All *P*-values chi-square tests, women vs men.

Pressure ulcers grade I--IV developed during hospital stay.

###### 

Crude effect of preoperative variables on pressure ulcer, cardiac complication, and pneumonia

  Binary variable                                                                                                                        Pressure ulcer   Cardiac complication   Pneumonia                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------- ---------------- ---------------------- ------------------------------------------------------ ----- ------------ ------------------------------------------------------ ----- ------------- ------------------------------------------------------
  **Baseline**                                                                                                                                                                                                                                                                                                                        
  Sex, male vs female[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                                        1.2              (0.9--1.6)             0.2                                                    1.4   (1.1--1.9)   0.016                                                  2.7   (1.9--3.8)    \<0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}
  Age, 85--103 vs 65--84[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                                     1.4              (1.1--1.8)             0.003[\*](#tfn12-cia-10-1259){ref-type="table-fn"}     1.3   (1.0--1.6)   0.06                                                   1.2   (0.8--1.7)    0.3
  Residence, institutional vs own home[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                       1.4              (1.1--1.8)             0.012                                                  0.8   (0.6--1.6)   0.3                                                    1.2   (0.8--1.8)    0.3
  ADL, assisted vs independent[a](#tfn14-cia-10-1259){ref-type="table-fn"} (Katz A--B vs C--G)                                           1.6              (1.2--2.0)             0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}     0.9   (0.7--1.2)   0.5                                                    1.4   (0.9--2.0)    0.09
  Fracture type, extracapsular vs intracapsular[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                              1.2              (1.0--1.5)             0.1                                                    0.9   (0.7--1.1)   0.3                                                    1.1   (0.8--1.5)    0.7
  ASA classification, 3--4 vs 1--2[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                           1.4              (1.1--1.8)             0.013                                                  2.2   (1.6--3.0)   \<0.001                                                2.5   (1.6--3.7)    \<0.001
  Time to surgery, 0--1 day vs 2 or more days[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                1.6              (1.3--2.1)             \<0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}   1.7   (1.3--2.3)   \<0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}   1.5   (1.0--2.1)    0.045
  **Presence vs absence of specific concomitant disease**                                                                                                                                                                                                                                                                             
  Cardiovascular disease                                                                                                                 1.1              (0.9--1.4)             0.42                                                   2.6   (1.9--3.5)   \<0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}   1.1   (0.8--1.6)    0.7
  Stroke                                                                                                                                 1.0              (0.8--1.4)             0.9                                                    1.1   (0.8--1.5)   0.7                                                    1.1   (0.7--1.7)    0.7
  Pulmonary disease                                                                                                                      1.5              (1.1--2.0)             0.006[\*](#tfn12-cia-10-1259){ref-type="table-fn"}     2.1   (1.5--2.8)   \<0.001                                                2.7   (1.9--3.9)    \<0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}
  Renal disease                                                                                                                          1.2              (0.7--2.0)             0.6                                                    1.5   (0.9--2.6)   0.6                                                    1.2   (0.5--2.7)    0.6
  Diabetes                                                                                                                               0.8              (0.6--1.2)             0.4                                                    1.2   (0.8--1.8)   0.3                                                    1.1   (0.6--1.7)    0.9
  Rheumatoid arthritis                                                                                                                   0.8              (0.5--1.3)             0.3                                                    1.2   (0.7--2.0)   0.4                                                    1.1   (0.6--2.1)    0.8
  Parkinson's disease                                                                                                                    1.4              (0.8--2.6)             0.3                                                    0.8   (0.4--1.7)   0.5                                                    1.9   (0.9--4.2)    0.08
  Malignancy                                                                                                                             1.3              (1.0--1.8)             0.065                                                  1.3   (1.0--1.9)   0.08                                                   1.3   (0.8--2.0)    0.3
  Cognitive function,[\*\*](#tfn13-cia-10-1259){ref-type="table-fn"} dysfunction vs normal[a](#tfn14-cia-10-1259){ref-type="table-fn"}   1.5              (1.2--2.0)             0.001                                                  1.6   (1.2--2.1)   0.002[\*](#tfn12-cia-10-1259){ref-type="table-fn"}     2.4   (1.6--3--6)   \<0.001[\*](#tfn12-cia-10-1259){ref-type="table-fn"}
  **Presence of additional complications and mortality**                                                                                                                                                                                                                                                                              
  Number of complications, 2 or more vs 1[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                    1.6              (1.2--2.0)             \<0.001                                                2.6   (1.8--3.1)   \<0.001                                                3.1   (2.0--4.7)    \<0.001
  Mortality within 30 days, yes vs no[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                        2.0              (1.5--2.8)             \<0.001                                                3.9   (2.9--5.4)   \<0.001                                                2.6   (1.7--3.9)    \<0.001
  Mortality 0--4 months, yes vs no[a](#tfn14-cia-10-1259){ref-type="table-fn"}                                                           1.6              (1.2--2.2)             0.001                                                  2.5   (1.8--3.3)   \<0.001                                                2.2   (1.5--3.2)    \<0.001

**Notes:** All *P*-values chi-square tests.

Variables still significant after adjusting for associated baseline variables.

According to the Short Portable Mental Status Questionnaire (0--7 vs 8--10).

Reference group.

**Abbreviations:** ASA, American Society of Anesthesiologists; ADL, activities of daily living; CI, confidence interval; OR, odds ratio.

###### 

Logistic regression models of baseline variables associated with the most frequent complications

                                                                                                                  Urinary tract infection   Pressure ulcer   Cardiac complication   Pneumonia                                                                          
  --------------------------------------------------------------------------------------------------------------- ------------------------- ---------------- ---------------------- ----------- ------------ --------- ----- ------------ --------- ----- ------------ ---------
  Sex                                                                                                                                                                                                                                                                  
   Female[b](#tfn17-cia-10-1259){ref-type="table-fn"}                                                             1                                                                                                                                 1                  
   Male                                                                                                           0.7                       (0.5--0.9)       0.003                                                                                  2.4   (1.7--3.6)   \<0.001
  Age                                                                                                                                                                                                                                                                  
   65--84[b](#tfn17-cia-10-1259){ref-type="table-fn"}                                                             1                                                                 1                                                                                  
   \>85                                                                                                           1.2                       (0.0--1.5)       0.034                  1.4         (1.1--1.8)   0.008                                                     
  ADL                                                                                                                                                                                                                                                                  
   Independent[b](#tfn17-cia-10-1259){ref-type="table-fn"} (Katz A--B)                                                                                                              1                                                                                  
   Dependent (Katz C--G)                                                                                                                                                            1.6         (1.2--2.1)   0.001                                                     
  Time-to-surgery                                                                                                                                                                                                                                                      
   0--1 day[b](#tfn17-cia-10-1259){ref-type="table-fn"}                                                                                                                             1                                  1                                               
   1 days                                                                                                                                                                           1.6         (1.2--2.1)   \<0.001   1.6   (1.2--2.2)   0.001                        
  Cardiovascular disease                                                                                                                                                                                                                                               
   No[b](#tfn17-cia-10-1259){ref-type="table-fn"}                                                                                                                                                                      1                                               
   Yes                                                                                                                                                                                                                 2.2   (1.5--3.0)   \<0.001                      
  Pulmonary disease                                                                                                                                                                                                                                                    
   No[b](#tfn17-cia-10-1259){ref-type="table-fn"}                                                                                                                                   1                                  1                            1                  
   Yes                                                                                                                                                                              1.6         (1.2--2.2)   0.003     2.0   (1.4--2.8)   \<0.001   2.8   (1.8--4.2)   \<0.001
  Cognitive function                                                                                                                                                                                                                                                   
   Normal (SPMSQ[a](#tfn16-cia-10-1259){ref-type="table-fn"} 8--10)[b](#tfn17-cia-10-1259){ref-type="table-fn"}                                                                                                        1                            1                  
   Dysfunction (SPMSQ 0--7)                                                                                                                                                                                            1.5   (1.1--2.0)   0.006     2.5   (1.6--3.8)   \<0.001

**Notes:**

The SPMSQ.

Reference variable.

**Abbreviations:** ADL, activities of daily living; CI, confidence interval; OR, odds ratio; SPMSQ, Short Portable Mental Status Questionnaire.
